In early axSpA vs non-axSpA CBP, 2 year spinal x-ray progression was minimal in both groups. But on MRI, fat lesions increased significantly in axSpA (0.16 units/yr vs –0.02), with 15% having ≥3 lesions at 2 year vs 1% in non-axSpA. Fat lesions may signal early structural https://t.co/zvgU1Gt0po

• https://x.com/synovialjoints/status/1983564490311696460/photo/1

New biomarkers in axSpA. In early axSpA (DESIR cohort), higher baseline Phospholipid transfer protein (PLTP) activity was linked to sacroiliac radiographic progression over 5 years. Lower zonulin and lipopolysaccharides (LPS) levels also associated with progression. Highlights https://t.co/1uBtR4QA97

• https://x.com/synovialjoints/status/1983556936080507088/photo/1

Clinical Year in Preview SpA: no difference in efficacy rotating vs switching bDMARD MoA for next steps @RheumNow #ACR25 #LB09 https://t.co/shCLgk7Yqz

• https://x.com/JihaRheum/status/1983553108535136270/photo/1

In a U.S. axSpA cohort (n=4,799), women had a 24% higher adjusted risk of TNFi discontinuation vs men especially under age 65. No sex differences seen for IL-17i or JAKi, though sample sizes were small. Highlights need for sex-informed treatment strategies. Abstract#2634 https://t.co/58Dw3nFCsf

• https://x.com/synovialjoints/status/1983549391203119443/photo/1

Use of AI in AxSpA imaging for diagnosis. ASembleNet, a hybrid deep learning model, achieved 99% accuracy on coronal and 98.1% on axial MRI for AS classification, outcomes higher than ResNet50, Xception, and InceptionV3. Validated on ASAS cases, with Grad-CAM interpretability and https://t.co/yU8shaIdP2

• https://x.com/synovialjoints/status/1983541835537744306/photo/1

What's the latest in PsA? https://t.co/I8ZgRQpVy6 Great review for whats new in PsA by @drpnash Looking forward for Large IL23-Axial study results. @RheumNow #ACR25

• What's the latest in PsA?

Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts JAKi use: ⬆️incidence of HZ infxn but not significant; ⬆️all-cause mortality (HR 4.94) and GI bleed (p=0.04) Individualize tx. consider potential complications #ACR25 @RheumNow Abs2633 https://t.co/pjKAazQFwW

• https://x.com/RHEUMarampa/status/1983305923268325583/photo/1
• https://x.com/RHEUMarampa/status/1983305923268325583/photo/1
• https://x.com/RHEUMarampa/status/1983305923268325583/photo/1

Sex differences in 💊 d/c in axSpA from the RISE registry 🔅Females - ⬆️discontinuation risks for TNFi 🔅No sex differences seen in dc risks for IL17i and JAKis 🔅Young females discontinued faster than males Gender diff in SpA can guide tx decisions #ACR25 @RheumNow Abs2634 https://t.co/kcXfZrU4zI

• https://x.com/RHEUMarampa/status/1983316548896076155/photo/1
• https://x.com/RHEUMarampa/status/1983316548896076155/photo/1

In a retrospective TrinetX analysis of 3 year safety outcome in AS, JAKi use was linked to higher mortality and GI bleeding vs TNFi, but lower malignancy risk. Infection rates were similar, with a trend toward more herpes zoster in JAKi users. Abstract#2633 @RheumNow #ACR25 https://t.co/pPY0wpAKA3

• https://x.com/synovialjoints/status/1983270044395073970/photo/1